View all IBC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recap
for Community Practice Connections™: 14th Annual International Congress on the Future of Breast Cancer® focuses on areas of clinical challenge faced by practicing oncologists. A brief overview of trial data, along with expert perspective, are provided in these summaries.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Eisai, Genentech, Genomic Health, Inc., Lilly, Merck & Co., Inc., Nektar Therapeutics, Novartis Pharmaceuticals Corporation, and Puma Biotechnology, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Community Practice Connections™: 14th Annual International Congress on the Future of Breast Cancer®


Release Date: October 1, 2015
Expiration Date: October 1, 2016
Media: Internet - based

Activity Overview

Community Practice Connections™: 14th Annual International Congress on the Future of Breast Cancer® is a series of short video interviews with leading experts in the treatment of breast cancer, who address a variety of questions commonly faced by practicing community oncologists.

CME Activity Table of Contents

  • Checkpoint Inhibition in Triple-Negative Breast Cancer
    Rita Nanda, MD
    Section of Hematology/Oncology
    The University of Chicago Medical Center
    Chicago, IL
     
  • Emerging Strategies for Triple-Negative Breast Cancer
    Joyce A. O'Shaughnessy, MD
    Co-Director, Breast Cancer Research
    Baylor Charles A. Sammons Cancer Center
    Texas Oncology
    The US Oncology Network
    Dallas, TX
     
  • Early-Stage, HER2-Positive Breast Cancer
    Sara Tolaney, MD, MPH
    Instructor in Medicine
    Dana-Farber Cancer Institute
    Harvard Medical School
    Boston, MA

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:

  • Integrate biomarkers, molecular assays, and other risk assessment tools in treatment decision making for breast cancer, when appropriate
  • Personalize treatment utilizing targeted therapies, when appropriate, based on predictive and prognostic molecular markers through multiple lines of therapy
  • Review current standards and emerging data regarding systemic therapies for the treatment of early-stage, locally advanced, and metastatic breast cancer
  • Incorporate systemic therapies for breast cancer (including endocrine, cytotoxic, targeted, and bone-modifying agents) into individualized treatment plans for patients based upon an evaluation of efficacy and safety, as well as patient and tumor characteristics

Faculty, Staff, and Planners' Disclosures

Faculty

Rita Nanda, MD
Assistant Professor, Department of Medicine 
Section of Hematology/Oncology
The University of Chicago Medical Center
Chicago, IL
Disclosure: No relevant financial relationships to disclose.
 

Joyce O'Shaughnessy, MD
Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
The US Oncology Network
Dallas, TX
Disclosure: Consultant: Arno Therapeutics, AstraZeneca, Celgene Corporation, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Lilly, J&J, Merrimack, Novartis, Pfizer, Roche, Sanofi, Takeda Pharmaceutical, Medfusion
 

Sara Tolaney, MD, MPH
Instructor, Department of Medicine
Harvard Medical School
Attending Physician, Medical Oncology  
Dana-Farber Cancer Institute
Boston, MA
Disclosure: Research Support: Genentech; Consultant: Lilly, Pfizer, Genentech


The following individuals have no relevant financial relationships with commercial interests:

The staff of PER®, Ann C. Lichti, CHCP; Kim Farina, PhD; Michael Perlmutter, PharmD, MS

Accreditation/Designation of Credit Statement

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Eisai, Genentech, Genomic Health, Inc., Lilly, Merck & Co., Inc., Nektar Therapeutics, Novartis Pharmaceuticals Corporation, and Puma Biotechnology, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728
Filter By